In October 2013, the International Life Sciences Institute -Health and Environmental Sciences Institute Immunotoxicology Technical Committee (ILSI-HESI ITC) held a one-day workshop entitled, ''Workshop on Cytokine Release: State-of-the-Science, Current Challenges and Future Directions". The workshop brought together scientists from pharmaceutical, academic, health authority, and contract research organizations to discuss novel approaches and current challenges for the use of in vitro cytokine release assays (CRAs) for the identification of cytokine release syndrome (CRS) potential of novel monoclonal antibody (mAb) therapeutics. Topics presented encompassed a regulatory perspective on cytokine release and assessment, case studies regarding the translatability of preclinical cytokine data to the clinic, and the latest state of the science of CRAs, including comparisons between mAb therapeutics within one platform and across several assay platforms, a novel physiological assay platform, and assay optimization approaches such as determination of FcR expression profiles and use of statistical tests. The data and approaches presented confirmed that multiple CRA platforms are in use for identification of CRS potential and that the choice of a particular CRA platform is highly dependent on the availability of resources for individual laboratories (e.g. positive and negative controls, number of human blood donors), the assay through-put required, and the mechanism-of-action of the therapeutic candidate to be tested. Workshop participants agreed that more data on the predictive performance of CRA platforms is needed, and current efforts to compare in vitro assay results with clinical cytokine assessments were discussed. In summary, many laboratories continue to focus research efforts on the improvement of the translatability of current CRA platforms as well explore novel approaches which may lead to more accurate, and potentially patient-specific, CRS prediction in the future.
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Introduction
As a result of the CD28 superagonist TGN 1412 monoclonal antibody (mAb) cytokine storm incident in 2006, cytokine release assays (CRAs) have become more commonly used as hazard identification and risk assessment tools for therapeutic candidates, particularly mAbs with the potential to elicit adverse pro-inflammatory cytokine responses in patients [1] [2] [3] . Although cytokine release syndrome (CRS) is a relatively rare event in the clinic, evaluating the potential of certain novel therapeutic mAbs to cause CRS is now part of preclinical safety testing [4] . Severe CRS is reported to have occurred in approximately 50% of recipients administered muromonab-CD3 (OKT3, an anti-CD3 mAb), before the introduction of high-dose corticosteroid pre-treatment [5] , although in subsequent protocols using a lower dose, pretreatment with anti-inflammatory agents and a slower infusion rate also reduced the risk. Moderate-tosevere CRS is reported in a small number of multiple sclerosis patients given alemtuzumab (Campath-1H Ò ), an anti-CD52 mAb [6] . Other therapeutic mAbs currently in use such as the tumor necrosis factor a (TNFa) antagonists infliximab, adalimumab and certolizumab pegol (Remicade Ò , Humira Ò and Cimzia Ò respectively) and many others such as bevacizumab (Avastin Ò ) and natalizumab (Tysabri Ò ) are not associated with CRS [4, 7] . Thus, in terms of predicting the safety of novel therapeutic mAbs in man, the CRA should ideally differentiate between mAbs with moderate-to-severe clinical risk (e.g. infliximab < alemtuzumab < muromonab-CD3 (Orthoclone OKT3) < TGN 1412).
Significant progress has been made in designing and developing improved methods for CRAs as a result of the CD28 superagonist TGN 1412 incident. In 2007, a solid-phase CRA, which involves the co-incubation of human peripheral blood mononuclear cells (PBMCs) with mAbs that have been dry-coated onto a tissue culture plate, was shown to be predictive for the cytokine release potential of TGN 1412 [8] . In 2009, the European Medicines Agency (EMA) held a workshop to discuss in vitro CRAs, with the conclusion that while a specific assay could not be endorsed at that time, CRAs have a place in predicting the effect of a product in humans [9] . Currently, a number of in vitro assay formats can be considered when evaluating the potential for cytokine release for hazard identification by a novel therapeutic. Various CRA platforms have been designed to identify mAbs that can be associated with CRS, however, not all CRA platforms can discriminate between mAbs inducing mild or moderate cytokine release, nor can they be used to determine a threshold where the levels of cytokines released may be associated with serious adverse events in humans. The diversity in the modes of action of specific drugs in the induction of cytokine release may require the availability of adapted or flexible CRA platforms to identify potential hazard in the clinic for a particular therapeutic candidate. As pharmaceutical companies become more familiar with the mechanisms related to mAb-induced cytokine release, new assays, platforms and data interpretation approaches are being adopted.
Considerable progress has been made in understanding mechanistic aspects of CRS as well as in developing CRA formats suitable for hazard identification. Thus, the International Life Sciences Institute -Health and Environmental Sciences Institute Immunotoxicology Technical Committee (ILSI-HESI ITC) Cytokine Release Assay Working Group set out to address the scientific issues pertaining to CRA conduct and CRS risk assessment in a multipronged approach. First, in 2013, ILSI-HESI ITC sponsored a survey of pharmaceutical companies, contract research organizations, and academic laboratories that demonstrated that a variety of in vitro assay approaches were used, including testing strategies, assay formats and reporting and interpretation of CRA data which was subsequently published [2] . The survey indicated that variations in assay design include solution and/or solid phase based assays, the use of either various dilutions of whole blood (WB), PBMCs, or peripheral blood leukocytes (PBLs) as responder cells, and in some cases, the capture of mAbs on plates or beads via Fc using protein A or antibodies to Fc. The survey also indicated that positive CRA controls vary across laboratories with many using anti-CD3 reagents, while others use anti-CD28 superagonist mAbs (such as TGN 1412 homologs) or LPS. Some laboratories also include other marketed mAbs as positive controls. Negative controls include phosphate buffered saline, tissue culture medium, isotype mAb controls or marketed mAbs not known to cause clinical cytokine release. Data readouts vary across laboratories from concentration of cytokines (e.g. pg/mL), ratios relative to negative controls and/or rank order comparison to other mAbs tested. Overall the results from the survey highlighted that there are no standard approaches, and the alignment of technical procedures for frequently used formats may pave the way for a more harmonized assay system. Next, on October 22, 2013, in Silver Spring, Maryland, the ILSI-HESI ITC Cytokine Release Assay working group sponsored a 1-day workshop entitled, ''Workshop on Cytokine Release: State-of-theScience, Current Challenges and Future Directions". This workshop brought together 93 experts in the field from pharmaceutical, academic, health authority, and contract research organizations to discuss novel technologies, experimental designs, practices and scientific challenges. The workshop included both oral and poster presentations of the latest science concerning CRA design, use, and interpretation, and concluded with an open panel discussion featuring the speakers. Topics presented encompassed a regulatory perspective on cytokine release and assessment, 2 case studies regarding the translatability of preclinical cytokine data to the clinic, and the latest state of the science of CRAs, including comparisons between mAb therapeutics within one platform and across several assay platforms, a novel physiological assay platform, and assay optimization approaches such as determination of FcR expression profiles and use of statistical tests. This manuscript summarizes the scientific presentations and provides a current view on the approaches being adopted to identify the risk of CRS for novel therapeutic candidates.
Cytokine release and assessment: a regulatory perspective
Following the TGN 1412 incident, testing for cytokine releaseinducing activity has been increasingly included in the nonclinical studies conducted to support clinical testing of mAbs [1] . Results of in vitro cytokine release testing are now frequently included in regulatory submissions when the therapeutic target is characterized as being involved in immune activation. Further, CRA results are also often submitted for mAbs with targets that have not been pharmacologically characterized as immune activators but are expressed on immune cells, or for products such as immune checkpoint inhibitors that are designed to disrupt immune inhibitory signals [2] . During the workshop, both Whitney Helms from the US Food and Drug Administration and Gabriele Reichmann from the Paul Ehrlich Institute described cytokine release and assessment from a regulatory perspective.
The conclusions from the EMA 2009 cytokine release workshop (that cytokine release assays have a place in predicting the potential of a product to trigger cytokine release in humans [9] ) suggest that assays should be customized taking into account the degree of knowledge of the mechanism of action of the product. Data derived from these assays should be considered for hazard identification purposes rather than for accurate and reliable risk quantification purposes. Further regulatory guidance on cytokine release testing has not been developed in the EU and there are still open questions regarding the products for which investigators should perform cytokine release testing and which assay format(s) they should use. Similarly, the United States Food and Drug Administration (FDA) does not currently have a requirement for any particular assay that must be used for the assessment of cytokine release. When FDA has requested cytokine assessments, sponsors have commonly been referred to Stebbings et al. and Römer et al. for information on the design of in vitro testing methods [8, 10] .
In an effort to refine the need for assessment of cytokine release and the recommendations for the methodological requirements for doing so, the regulatory experience with cytokine release testing at Paul-Ehrlich-Institute was reviewed based on clinical trial applications for first-in-human studies with mAbs and related products. Based on this review, in vitro cytokine assessment would be recommended for mAbs targeting cellular receptors, especially if expressed on immune cells. In addition, the mode of action of the individual product should be taken into account to estimate its cytokine-inducing risk. An antagonistic mAb would be associated with a lower risk, while a higher cytokine-inducing risk would be attributed to a mAb with cytotoxic effector function, or a mAb which is agonistic or immunostimulatory. For this latter group of products, knowledge of the mechanism of action should prevail with regard to risk assessment in the case of negative in vitro cytokine release data. In addition, in vitro cytokine release data might be recommended when manufacturing changes are made to a clinical candidate with known or mechanistic potential for cytokine release or when two products for which there is limited clinical experience are proposed for use in combination, even if the individual mAbs have not demonstrated cytokine release potential.
When considering the format of the in vitro CRA, a definitive recommendation would not be made as it needs to be relevant to the understanding of mechanism of action of the product being tested. Assays using WB or PBMCs would be acceptable; while WB assays are considered more physiological, PBMC assays may be more sensitive to reveal a cytokine signal. Depending on the mechanism of action (e.g. products targeting CD3 or T-cell costimulatory ligands), other assay formats can be more appropriate. Regarding the presentation of the mAb, a soluble assay format would be sufficient in the event of positive signal in the CRA. Otherwise, some form of cross-linking of the mAb would be recommended. The cytokines to be measured are dependent on the target and anticipated mechanism of action of the therapeutic mAb. For example, from data submitted to the Paul-Ehrlich-Institute, it is known that several mAbs associated with cytokine release in vivo induce the expression of IL-6, IL-8, and/or TNF-a in CRAs in vitro.
One of the most difficult issues is the interpretation of CRA results. Currently, FDA and EMA have not required that CRA be conducted under Good Laboratory Practice regulations, in part because no standard or generally-accepted assays are available. Assay outcomes show high inter-donor variability in responses, making the inclusion of an adequate number of donor samples an important factor in the interpretation of the assay, however, a definitive recommendation on the number of donors to be tested is not possible as this would vary with assay read-outs and performance. Also, the absolute levels of the produced cytokines vary depending on the platform used, and it is often difficult to say what constitutes a true positive result. For this reason, one critical aspect of the study design is the inclusion of positive and negative controls. While LPS or PHA are sometimes used as positive control reagents, the inclusion of control mAbs that are known to induce cytokine-release is generally considered more appropriate. Selection of the control mAb could depend on the mechanism of action of the product to be evaluated, e.g. muromonab-CD3 or TGN 1412 for T cell targeting products; alemtuzumab and/or rituximab for products with cytotoxic effector function. Data interpretation can also be enhanced by the inclusion of control mAbs that have been shown clinically not to result in cytokine induction, or that have some potential to induce cytokines, but not to a level that has resulted in clinically adverse events.
Despite the challenges associated with interpretation of CRA data, cytokine release assessment has become an increasingly utilized tool used for the prediction of product safety, particularly for biologic products. The finding of positive results in a CRA raises the possibility that the determination of the starting dose and dosing regimen need to take CRS potential into consideration. The development of a well-established assay or assays that can be used to reliably predict the potential of a product to initiate cytokine release syndrome, therefore, remains an area of ongoing interest from a regulatory perspective.
Translatability of preclinical cytokine data
Interpretation of CRA data may be challenging for reasons that include the inability to discriminate between a mild and moderate response in patients, or to determine a threshold of cytokine production in vitro that will translate to a severe adverse event in humans. Despite these challenges, cytokines are included in nonclinical and clinical studies as safety biomarkers. Although the translatability of the nonclinical cytokine data is not absolute, in some cases they are predictive of risk in human populations. Based on this mechanism of action, the ability of MEDI-565 to induce proliferation of T cells and production of cytokines in an in vitro PBMC assay system was investigated as part of the nonclinical safety assessment. In vitro, the MEDI-565 concentration response relationship for T-cell activation, redirected cancer cell lysis, and concomitant cytokine release was analyzed using PBMCs from healthy human donors. Activation of T cells, cancer cell lysis, and concomitant cytokine release by MEDI-565 exclusively occurred in the presence of cancer cells expressing CEA. Results from these in vitro studies on human PBMCs demonstrated that the ability of MEDI-565 to induce cytokine release and proliferation of T cells required engagement of both CD3 on T cells and CEA on target cells. These in vitro cytokine release results were used as part of a strategy to determine a minimal anticipated biological effect level (MABEL) and to select a reasonable maximal safe starting dose for MEDI-565.
Case study #2: Translatability of pre-clinical cytokine data to clinical studies
In another case study presented by Marie-Soleil Piche (Charles River Laboratories), cytokine data obtained in rats and monkeys partially translated to findings in humans. This case study was divided into 3 sections: (1) initial nonclinical studies in rats and monkeys; (2) follow up nonclinical studies in rats and monkeys with a modified compound; (3) initial clinical study with the modified compound. The test article was designed to treat patients with advanced solid tumors by targeting two distinct pathways of tumor progression involving cell proliferation and angiogenesis.
Several toxicity findings in the mid-and high-dose groups were noted in the initial rat and monkey studies, including mortality, reduced activity, changes in the liver, kidney, adrenals, spleen, lymph node, and bone marrow, reduced food consumption, increased white blood cell counts and altered coagulation. Serum TNF-a levels were higher compared to historical data in several animals from different dose groups in both species, however, in the rat nonclinical study, most animals from the control group also had higher levels of TNF-a. Therefore, given the inter-animal variability observed, the TNF-a responses in rats were not considered to be related to test article administration. Increases in serum IL-6 concentrations were observed in both the rat and monkey studies, while increases in serum IFN-c were only observed in rats. Evidence of complement activation following dosing was also noted in the monkey study: C3a and Bb levels were higher following dosing while total Hemolytic Complement activity (CH50) levels were generally decreased. In both species, partial reversibility was observed for some findings following the recovery period. Based on the observations from both nonclinical studies, the 1st generation test article was modified to reduce its toxicity, and the modified test article (2nd generation product) was evaluated in a subsequent rat and monkey nonclinical studies.
In the follow up rat and the monkey studies, using the modified test article, microscopic changes in the liver, kidney, spleen and BM were still observed but the clinical signs were generally less severe than those observed with the original test article. Increases in C3a and Bb fragments were still observed in monkeys following dosing. Serum cytokine levels of IL1-b, TNF-a, and IFN-c were below or close to the lower limits of quantitation (LLOQ) in both species, while IL-6 remained high following dosing in monkeys. Therefore, the rat seemed less sensitive than the monkey to the modified test article. Release of cytokine and inflammation markers, such as creactive protein, generally occur at lower levels in rats than in monkeys [11] . Overall, these data suggested that the 2nd generation product was less toxic than the original test article, and the 2nd generation product was brought forward for testing in a Phase I clinical trial.
Patients received 4 cycles of treatment. Each cycle was comprised of 2 doses of the product administered 2 weeks apart. If there were no dose limiting toxicities during the first cycle, the study could proceed with dose escalation to the next cohort. Blood samples for cytokine analysis were taken at pre-dose as well as at 2, 6, and 24 h post-dose following the first 2 cycles of treatment, corresponding to four doses of product. Serum levels of IL-1b, IL-1RA, IL-12, IP-10, IFN-a, IFN-c and G-CSF were analyzed. For most patients, circulating levels of IL-1b, IL-12, IFN-a and IFN-c were below the LLOQ, however, IL6 and IL-1RA levels were higher 6 h following dosing, which was consistent with the circulating IL-6 elevations observed in the monkey. Therefore, in this case study, a certain degree of similarity existed between the cytokine data generated in nonclinical (rats and monkeys) and clinical studies. In general, monkeys were more predictive of a potential cytokine release than rats. Indeed, IFN-c and IL-1b were below the LLOQ in both the clinical and the monkey studies while IL-6 level was increased in both the clinical and the monkey studies.
State of the science

Comparison of cytokine release across mAb therapeutics
Despite wide-spread use of solid-phase CRAs in the evaluation of certain therapeutic mAbs, little comparative data exists that evaluates the value of this approach for predicting CRS. During the workshop, Richard Stebbings presented the work carried out at the National Institute for Biological Standards and Controls (NIBSC) towards the comparison of cytokine release across multiple mAb therapeutics.
TGN 1412 was compared to muromonab-CD3, alemtuzumab and 9 other mAbs using a wet-coat solid-phase CRA that utilizes non-tissue culture treated 96 well polypropylene microtitre plates to achieve high binding density as an alternative to air drying [5] . Culture supernatants from human peripheral blood mononuclear cells added to these tissue culture plates were assayed for cytokine release after 24-72 h. Only TGN 1412 and muromonab-CD3 stimulated T-cell mediated cytokine release characterized by significant (p < 0.0001) release of IL-2 and 9 other cytokines. Compared to muromonab-CD3, TGN 1412 stimulated only IL-2 release to a significantly greater extent (p < 0.0001). The ability of TGN 1412 to stimulate 27.46-fold more IL-2 release than muromonab-CD3 correlated with its ability to stimulate 24.67 times more CD4+ Tcells producing this cytokine, implying a greater level of T cell activation. However, TGN 1412 appears not to stimulate more T cells than muronomab-CD3 since other cytokine release is comparable, but rather it overrides CD4+ T helper cell cytokine memory (e.g. Th0, Th1, Th2, Th17, Th22 polarization) to cause a wide range of subsets to co-release IL-2 that otherwise would not, likely due to the ability of CD28 to promote IL-2 mRNA stability [8] . This difference implies that massive IL-2 release was responsible for the severity of the CRS associated with TGN 1412, compared to muromonab-CD3. No significant IL-2 release was observed with alemtuzumab, but significant (p = 0.0177) non-T cell mediated TNF-a release was observed. These results demonstrate that the PBMC solid-phase cytokine release assay is able to predict T-cell mediated cytokine release associated with the use of therapeutic mAbs. A complicated picture is emerging in which multiple mechanisms of cytokine release involving different subsets of immune cells are involved in CRS.
Comparison of cytokine release across platforms
As assay systems differ across laboratories, a comparison of three platforms was carried out that directly compared the responses to mAbs with a strong association with CRS (e.g. alemtuzumab, OKT3, CD28 superagonist), mAbs with weak or rare association with CRS (rituximab, trastuzumab), and a mAb with no established association with CRS (infliximab). Madeline Fort presented work carried out at Amgen to help address this question. The platforms chosen included a solid phase CRA with dry coating of mAb to wells [8, 12] , a solution phase CRA with high density PBMC pre-culture [10] , and a co-culture CRA of peripheral blood leukocytes (PBL) with endothelial cells [7, 12] (Table 1) .
For all of the CRA platforms, cytokines were assessed using a multiplex array Luminex Magnetic Bead Panel, EMDmillipore Corp.) Detection of concentration-dependent P 3-fold increases above negative controls of more than 1 cytokine using PBMCs or PBL from 3 or more donors was deemed to be a positive cytokine response. c Not determined.
Panel). As summarized in Table 1 , in the solid phase CRA, alemtuzumab, muromonab-CD3, and rituximab produced proinflammatory cytokines as has been described in the literature [12] ; however, mAbs with weak or no established association with CRS in patients (infliximab and trastuzumab) as well as an antistreptavidin human IgG2 non-specific control mAb also produced pro-inflammatory cytokines, including TNF-a, IL-6, IL-8, and IL1b, at levels equivalent to muromonab-CD3 and rituximab with PBL from several donors, suggesting the possibility of false positives with this platform. High density pre-culture of PBMCs resulted in the detection of pro-inflammatory cytokines by soluble CD28 superagonist mAb in agreement with published results [10] . Co-culture of PBL with human umbilical vein endothelial cells (HUVEC) provided sufficient detection of T cell-associated cytokines such as IL-2, IL-4, IL-10, IFN-c, TNF-a, IL-6, and IL-8 from OKT3 and a CD28 superagonist mAb. In this platform, alemtuzumab induced IFN-c, TNF-a, IL-6, and IL-8 but not IL-2, which suggests that innate immune cells, such as natural killer cells, are the predominant targets over T cells for alemtuzumab. The PBL/ endothelial co-culture assay did not detect cytokine release in response to mAb with weak, rare, or no association with CRS in vivo, including infliximab, trastuzumab, and rituximab. Therefore, the PBL/endothelial cell co-culture CRA provided the best correlation for the clinical outcome of strong CRS potential for the therapeutic mAbs assessed that target immune-related cell surface receptors.
Physiological conditions may provide more in vivo relevance in newly developed assays
As some groups have made significant progress towards providing an optimal assay format to test biologics, one important, and ongoing, consideration is the extent to which assays reflect the physiological environment. To achieve a more physiological environment, endothelial cells and PBMCs are co-cultured and used for CRA testing [8, 12] . Some literature reports suggest that endothelial cell/PBMC co-culture is favorable, as this kind of assay reflects the cell interactions in vessels where cytokine release and vascular leak occur [7, 12] . Because mature endothelial cells in the body are found lining blood vessels, they cannot be obtained readily from healthy volunteers. Endothelial cells are therefore routinely grown from umbilical veins, which are used as the interface with PBMCs for cytokine release testing. This means that co-culture assays are comprised of heterologous mixtures of cells. Investigators at the National Heart and Lung Institute, Imperial College London, have generated the hypothesis, described during the workshop by Daniel Reed and Jane Mitchell, that this could result in a tissue mismatch that occurs when cells from one donor are mixed with those of another [13] , and that this might be responsible for some of the limitations of HUVEC/PBMC coculture assays. In line with this, others have also suggested that the use of heterologous co-culture assays is a potential limitation in endothelial cell/PBMC co-culture assays used to test for CRS responses [2] . Recently the investigators from Imperial College presented an assay that employs endothelial cells derived from adult progenitors, so-called blood outgrowth endothelial cells (BOEC) together with PBMCs from the same donor [14] . Importantly, this autologous BOEC/PBMC co-culture assay was found to respond to anti-CD28 superagonist mAb to release cytokines associated with CRS in a way that delineated responses from less severe cytokine storm causing mAbs such as alemtuzumab and non-cytokine storm causing mAb such as bevacizumab. Working together with Professor Richard Stebbings and the National Institute for Biological Standards and Control, the Imperial College team also recently demonstrated that this assay is superior to heterologous donor assays (HUVEC/PBMC co-cultures) [14] . The authors concluded that the improved 'signal to noise' response seen in their autologous BOEC/PBMC co-culture assay was a result of the removal of the confounding factor of tissue mismatch. Furthermore, unlike HUVEC/PBMC co-culture assays, BOEC/PBMC cocultures contain matched donor cells and can be used to study cytokine storm reactions in target patient groups. This is important, since recent work has shown that BOECs derived from patients with the lung conditions pulmonary hypertension [15] or chronic obstructive pulmonary disease [16] retain a disease phenotype in laboratory assays. In this way, BOEC/PBMC assays represent an optimal system for a personalized medicine approach and could be used to construct highly translatable co-culture assays. The challenge now will be to determine how to scale up these assays in order to produce an off-the-shelf prototype for broad use by the pharmaceutical industry.
Optimizing assay conditions for detection of cytokine release potential
Although significant progress in the use of bioassays to predict CRS has been made, to date no consensus exists on the optimal assay format that should be used when screening uncharacterized mAb therapeutics. Traditionally, the soluble phase CRA format (mAbs free in culture media with PBMCs) and the solid phase CRA format (mAbs immobilized to culture plate) have been utilized to assess responses mediated by either the Fc or Fab' portion of mAbs. However, following the difficulties in sensitively replicating the cytokine storm induced by TGN 1412, this may be an over-simplified approach which may not be appropriate for all mAbs.
Through the NC3Rs (National Center for 3 Rs) UK governmentfunded collaboration (CRACK-IT) the University of Southampton and Envigo CRS Ltd (''Envigo", formerly known as Huntingdon Life Sciences), represented at the meeting by Daniel Gliddon, is attempting to develop reliable and sensitive assays for the prediction of CRS. The approach comprises the evaluation of a range of assay formats suitable for measuring cytokine induction mediated by target or effector cells in response to leukocyte-expressed, tissue-expressed or soluble target antigens. The primary aim of the project is to develop an assay that can be applied to effectively predict the clinical outcome for a candidate mAb based on the individual characteristics of that mAb and to support this, a range of culture conditions and specific assessments are being investigated. These include the sensitive measurement of cytokine release, assessment of cellular proliferation, analysis of Fc gamma receptor (FccR) genotypes, assessing the proportions of key immune cell populations in donor samples and appropriate powering to enable statistical analysis. Work is currently focusing on the optimization of assay conditions using PBMC samples obtained from healthy donors by incubation with a range of mAbs known to be associated with CRS or control mAbs, and assessing for cytokine production and cell proliferation. Additionally, information on the FcR expression at both the cellular and genetic level for each donor is analyzed to determine their relationship to responses in the assay.
Results to date indicate that culture conditions supportive of reliable and sensitive assay formats for testing induction of cytokines associated with CRS may have been identified. Further, the pattern of cytokine production observed in the assays is specific to those cytokines associated with CRS clinically, including those cytokines induced by TGN 1412. Work is ongoing to optimize assay parameters and to fully analyze the impact of FccR expression on cytokine release. In investigating the mechanism of enhancement of PBMC responsiveness to TGN 1412 precultured at high density, the University of Southampton have recently shown monocyte upregulation of FcgRIIb as the prerequisite factor [17] , rather than increased T cell sensitivity or B cell expression of FcgRIIb as described by others [10, 18] . If successful, Envigo intends to validate the final assays and to provide them as an option for the nonclinical safety evaluation of novel mAb therapeutics.
Statistical analysis can provide guidance for optimized assay conditions
In providing insight towards optimizing assay conditions, Mindi Walker from Janssen described how statistical analysis can be applied to assist in experimental design and data analysis [19] . Statistical analyses were conducted on historical data generated from a WB assay which analyzed 11 cytokines using mAbs immobilized on protein A beads. The data set included 32 different test mAbs using 44 donors over 12 different experimental runs with runs containing between 3 and 8 unique donors. Review of the data set revealed that the data were approximately log normal and therefore, log transformation of the data would allow use of an Analysis of Variance (ANOVA) using Tukey's posttest, which is a more powerful statistical test than the Kruskal-Wallis ANOVA on ranks that was currently in use. Statistical analyses were conducted to look at sources of assay variation, to identify outliers, and to optimize powering of the assay. Results from a variance component analysis model showed that the greatest source of variation in the assay was inter-donor variation, and therefore assay power could be increased by increasing the number of donors in a given run. Additionally, power analysis results showed that running samples from 16 donors without replicate wells increased the power to detect smaller differences in cytokine responses between treatment groups than an assay setup of samples from 8 donors in triplicate wells. Power analysis should be performed on the CRA assay of choice to determine the number of donors and replicates needed to detect differences in a given laboratory. In general, donor to donor (inter-donor) variation is greater than within donor (intra-donor) variation and therefore increasing the donor number within a given run will increase assay power. Plate variation was also analyzed and results showed some variation, which was inconsistent across cytokines, in both the WB assay plate and the Meso Scale Discovery (MSD) cytokine analysis plate. In order to mitigate any plate effects that occur, plates may be arranged with samples from a specific donor in each row and treatments randomized to different columns for each new experiment. Results from the outlier analysis showed that visually unusual data points were within normal inter-donor variation, therefore, better understanding of the sources of variability among blood donors would increase assay robustness. In addition, the data were analyzed using 6 predictive modeling algorithms which included linear discriminant analysis (LDA), recursive partitioning (RP), neural networks (NN), support vector machines (SVM), random forests (RF), and naïve Bayes (NB). These models gave a probability of a new test compound being similar to compounds identified during model training as having no to mild CRS or moderate to high CRS potential. The retrospective analysis of the assay data identified areas for improvement in both the assay conduct and analysis of the data. The assay now has increased power to detect differences in treatments, data analysis has been optimized and includes more powerful statistical tests, individual runs that perform outside control limits or donor outliers can be identified, and plate effects have been mitigated. In addition, predictive modeling provided an independent and unbiased CRS prediction category which gave added confidence to the risk assessment for novel compounds. Implementation of these improvements, along with statistical approaches, has increased assay robustness and predictability to increase precision, and thus should increase confidence in CRS assays by regulatory authorities and clinicians. The analyses provide an example of statistical tests that should be performed on this type of data and hopefully inspire others to think about their assay setup and data analysis in new ways.
Discussion and future directions
Despite significant progress and groundbreaking research in the area of bioassays to predict the potential of a mAbs to cause a ''cytokine storm" in humans, many questions remain. The ILSI-HESI ITC Cytokine Release Assay Working Group survey that was conducted and presented at the workshop by Deborah Finco (Pfizer), in conjunction with a literature review, highlighted that no consensus exists on the optimal assay format to test the potential of novel mAbs to cause cytokine storm in patients [2] . Considerable variation in protocol design and assay format occurs across institutions carrying out such testing. Part of the on-going discussion regarding CRA platforms is whether there is a need to consolidate assay design and format, and establish uniform protocols for CRS testing. The availability of a standard assay platform for CRS prediction would allow the comparison of results for a wide variety of novel therapeutics by industry and regulatory scientists. However, there is ongoing debate in regards to which assay format is optimal for prediction of CRS potential. This debate includes the ability of an assay to rank order mAbs by perceived degree of CRS risk in patients, to mimic the pattern of cytokine release observed in vivo by a particular mAb, to recapitulate physiologically relevant (''in vivo-like") conditions, and the number of different WB/PBMC donors required for accurate predictive power [3, 10, 12, [19] [20] [21] [22] . Given the difference in mechanisms of action between different therapeutic mAbs, determination of whether a ''one-size-fits-all" approach is feasible would require enhanced understanding of technical procedures, practices, and performance, including positive and negative controls, data interpretation and clinical use. One outcome from the workshop has been the development of ''standard" positive and negative control mAbs for CRA qualification at the National Institute for Biological Standards and Controls (NIBSC, Hertfordshire, United Kingdom). Currently, these controls are being tested in a variety of CRA platforms, and if the controls demonstrate acceptable performance, these reagents will be available for use to the wider research community and will enable better cross-laboratory and cross-platform comparison of CRA results.
It is conceivable that, because of the unique mechanism of action of any mAb therapeutic, we will never be in a position to define an assay that will universally predict risk of cytokine storm. This raised a question among the workshop participants: are we correct in focusing so exclusively on assays appropriate for the mechanism of action of TGN 1412? Furthermore, assay platforms that are the most appropriate for mAb-mediated cytokine release may not be ideal for detection of cytokine release induced by other modalities. For example, Coch and colleagues determined that a WB assay format was preferable over PBMCs for detection of cytokine release by oligonucleotides which bind to toll-like receptors [23] . In addition, as described by Patricia Ryan in Case Study #1 above and in the literature, novel immunotherapies for cancer such as bispecific T cell engagers induce T cell activation and cytokine production only when target-expressing tumor cells are present and may require specialized assay formats to allow the sensitive detection of T cell activation for determination of a minimal acceptable biological effect level (MABEL) in patients [24, 25] .
One idea discussed at the workshop to promote confidence in CRA formats was the establishment of a database comprised of data from various CRAs and the subsequent results of in vivo cytokine tests in patients receiving therapeutic mAbs. This would require collecting the serum cytokine data from patients in clinical trials in a comprehensive and consistent manner in addition to the in vitro CRA data. Researchers at this conference, however, were able to present only limited clinical cytokine data due to the fact that samples are not routinely collected for this assessment in clinical trials and/or because such clinical data was not easily available within the organization. Since the workshop, the Nonclinical Biologics Subcommittee at the Center for Drug Evaluation and Research of the FDA has initiated a Cytokine Release Data Mining Project to use both nonclinical and clinical cytokine data to determine if CRA formats are good predictors of clinical outcomes; the results from this project will be very informative for the field. Another option to increase confidence in CRA formats may be to perform CRAs with toxicology species samples and measure cytokines in vivo during toxicology studies in that species. Correlates between toxicology species in vitro CRAs and in vivo data may further support the predictive results obtained with human cells and translatability to patients. While there is active research in this area by some groups, the predictive value of the CRA platform for human immune cells may still need to be confirmed with clinical cytokine data. Clearly, close cooperation and collaboration among clinical investigators and research laboratories is critical for confidence in the predictive value of any CRA platform.
It is generally agreed that there is need for a clearer understanding of the underlying immune networks that can allow for the escalation of the immune responses to the detriment of the organism itself. Pathologic immune response cascades have been observed with a variety of agents, including bacteria (e.g. sepsis), viruses (e.g. avian influenza, small pox), and medical interventions such as graft vs host disease and certain mAb therapeutics (OKT3, TGN 1412, alemtuzumab) [1, 5, 6] . A systems biology approach to understand the initiating events of immune cell activation that can lead to development of CRS may be necessary to truly understand all the possible ''triggers". This knowledge could then be applied to the in vitro CRA platforms: permitting the design of a CRA platform (or platforms) that will capture the most relevant potential immune signaling cascades for a particular mAb therapeutic target.
Finally, many fields of medicine and biotechnology are increasingly developing personalized approaches whereby drugs or doses are defined based on an individual patient's genes and characteristics. Examples include warfarin dose selection based on individual patient expression of the genes CYP2C9 and VKORC1 [26] , and Abacavir hypersensitivity based on HLA⁄B5701 expression [27] . As most CRA platforms utilize peripheral blood (either whole or isolated cell subsets), it is possible that a screening process could be designed for individual patients. This may be most relevant when the health status and/or genetic make-up of a particular patient may affect the CRS potential of novel therapeutic mAbs. For example, if the presence of autoimmune disease results in enhanced expression of a therapeutic target on immune cells, then use of healthy donor WB or PBMCs may not be appropriate for understanding CRS potential in patients. In such a scenario, testing the therapeutic in a CRA platform using immune cells from either a group of donors with autoimmune disease or from prospective patients enrolled in a clinical trial would be optimal. This approach, although an intriguing idea, could be very challenging logistically, especially in clinical trials with large numbers of patients. Growth in our understanding of the mechanisms underlying CRS in vivo should result in the development of in vitro CRA platforms that correlate to in vivo clinical cytokine measurements and greater confidence in translation of in vitro outcomes to the clinic.
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